600351 亞寶藥業
按盤價 
6.620 +0.010 (+0.151%) | 2025/09 - 九個月 人民幣(K¥) | 與去年同期 比較 | 2024/12 人民幣(K¥) | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | ||
| 營業總收入 | 1,708,712 | -19.46% | 2,686,038 | 2,909,765 | 2,718,135 | 2,763,962 | |
| 減：營業總成本 | 1,422,106 | -23.33% | 2,391,542 | 2,620,741 | 2,539,492 | 2,586,226 | |
| 其中:營業成本 | 817,879 | -20.10% | 1,297,853 | 1,226,342 | 1,199,376 | 1,077,119 | |
| 財務費用 | (2,513) | 463.64% | (814) | 3,223 | 10,829 | 14,763 | |
| 資產減值損失 | (66,395) | 875.53% | (42,163) | (93,749) | (68,059) | (31,668) | |
| 公允價值變動收益 | 1,086 | 937.25% | (2,847) | (2,582) | (3,541) | 1,335 | |
| 投資收益 | 1,557 | 1,794.24% | (188) | (2,764) | (631) | 13,538 | |
| 其中：對聯營企業和合營企業的投資收益 | (306) | 34.09% | (321) | (412) | (375) | (1,781) | |
| 營業利潤 | 253,259 | -12.18% | 299,953 | 226,335 | 123,548 | 203,217 | |
| 利潤總額 | 253,364 | -10.79% | 292,108 | 218,981 | 125,647 | 201,593 | |
| 減：所得稅費用 | 54,872 | -1.21% | 68,193 | 39,068 | 21,043 | 17,830 | |
| 淨利潤 | 198,491 | -13.12% | 223,916 | 179,914 | 104,604 | 183,763 | |
| 減：非控股權益 | (16,603) | 156.80% | (18,773) | (19,672) | (51) | (3,327) | |
| 股東淨利潤 | 215,094 | -8.44% | 242,688 | 199,586 | 104,655 | 187,089 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 0.307 | -5.40% | 0.340 | 0.260 | 0.140 | 0.240 | |
| 每股派息 (元) * | 0.200 | -- | 0.300 | 0.150 | 0.050 | 0.080 | |
| 每股淨資產 (元) * | 3.994 | -2.59% | 4.018 | 3.865 | 3.857 | 3.801 | |
| 審計意見 # | -- | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 07/01/2026 12:40 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
